CONMED Expands AirSeal Robotic Solution Indication for Intuitive da Vinci 5 Hex Cannula

Medtronic plc is trading at roughly 14.4 times forward earnings at $86.38 per share after raising its fiscal 2027 organic revenue growth and diluted non-GAAP EPS outlook in September. The company now expects organic revenue growth of 7.25% to 7.75% and full-year diluted non-GAAP EPS of $5.94 to $6.00, following first-quarter non-GAAP diluted EPS of $1.45 that came in ahead of guidance. Fiscal 2027 first-quarter revenue rose 13.7% organically to $9.8 billion, though Medtronic estimated that an extra fiscal week in the quarter contributed approximately $570 million to organic growth, making the headline rate look stronger than underlying recurring growth. Cardiovascular led the quarter with organic revenue up 18.9%, including 88% growth in Cardiac Ablation Solutions and 29.1% growth in Electrophysiology Therapies, while Neuroscience rose 9.3%, Medical Surgical grew 10.2%, and Diabetes rose 14.9% organically. The company has also expanded through the acquisitions of Scientia Vascular and SPR Therapeutics and announced further investments in robotic-assisted surgery and leaflet modification technology. Medtronic shares have declined more than 7% over the past 12 months, compared with a 17% gain for the broader market.

Zacks Investment Research has initiated coverage of SS Innovations International, Inc. SSII with a Neutral recommendation. The report notes the company's SSi Mantra Surgical Robotic System installed base reached 238 systems as of Sept. 8, 2026, up 42% from year-end 2025, while procedure volumes rose 79% to 14,103 over the same period. Revenues for the first six months of 2026 increased to $25 million from $15.1 million a year earlier, and gross profit rose to $12.4 million from $7 million. The SSi Mantra platform is now installed across 12 countries, with recent robotic surgery programs in Colombia and Sri Lanka, and supports more than 170 procedure types. Zacks also flagged persistent operating losses, including a net loss of $6.2 million in the first half of 2026, dependence on external financing, regulatory requirements for expansion into the United States and Europe, and competition from established surgical robotics manufacturers as key risks.

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

SS Innovations International reported 195 robotic telesurgeries performed with its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. Founder and CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.

Medtronic plc reported 13.7% organic and reported topline growth in its first quarter, with revenue reaching $9.756 billion and adjusted earnings of $1.45 per share. Double-digit year-over-year growth was seen across all major segments, with Cardiovascular up 19.5%, Diabetes up 16.9%, Neuroscience up 10.3% and Medical Surgical up 10%, though an extra fiscal week added approximately $570 million to quarterly revenue. CFO Thierry Piéton said the Cardiac Ablation Solutions segment is annualizing at more than $2 billion in revenue, and the unit surpassed $2 billion in trailing 12-month revenue in Q1 FY27, ahead of management's target. The company made a $700 million strategic investment in Cornerstone Robotics that includes rights to distribute the Sentire Surgical System in select markets outside the US, complementing its existing Hugo robotic-assisted surgery system. Medtronic carries a market capitalization of almost $109.3 billion, with $37.54 billion in revenue over the prior twelve months, an operating margin of 19.33% and a net margin of 13.93%; the stock trades at a trailing price-to-earnings multiple of 22x and a forward P/E of 14.93x. Hedge fund holdings rose to 67 in the second quarter of 2026 from 60 in the prior quarter, while BlackRock is the largest institutional investor with 114.02 million shares, or 8.91% of outstanding shares.

Intuitive Surgical's single-port platform is emerging as a meaningful growth franchise, with SP procedures climbing 61% year over year in the second quarter on strong momentum in the United States and Korea and early-stage adoption in Europe, Japan and Taiwan. The company placed 38 SP systems in the quarter, lifting its global installed base to 445 systems, and although Intuitive Surgical does not break out standalone SP figures, rising placements and robust procedure growth should soon make the platform a billion-dollar franchise alongside its multi-port business, which generated the majority of its $10 billion in 2025 revenues. Average U.S. SP system utilization rose 25% year over year in the second quarter, showing growth is increasingly driven by higher use of deployed systems rather than placements alone. Adoption of the SP stapler is accelerating, used in nearly 60% of eligible U.S. cases, up from just under 40% in the prior quarter, led by colorectal and thoracic procedures, with broad launches underway in Europe and Korea and a Japan launch likely beginning in the third quarter. Intuitive Surgical cited extended-range instruments, custom remote-center software and reach-assist software as key enablers of broader SP adoption, and SP placements rose to 38 in the second quarter from 23 a year earlier, driven mainly by U.S. and Japanese demand.